FDA approves Inflectra, a biosimilar to Remicade - FDA Press Releases

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

from Food and Drug Administration--Press Releases http://ift.tt/1SNUkUv
via IFTTT